belatacept

BACKGROUND In previous analyses of BENEFIT, a phase 3 study, belatacept-based immunosuppression, as compared with cyclosporine… Expand

BACKGROUND AND OBJECTIVES Prolonged use of calcineurin inhibitors (CNIs) in kidney transplant recipients is associated with renal… Expand

Belatacept, a costimulation blocker, may preserve renal function and improve long‐term outcomes versus calcineurin inhibitors in… Expand

Recipients of extended criteria donor (ECD) kidneys are at increased risk for graft dysfunction/loss, and may benefit from… Expand

Belatacept is a first-in-class co-stimulation blocker in development for primary maintenance immunosuppression. A Phase II study… Expand

Current success in organ transplantation is dependent upon the use of calcineurin‐inhibitor‐based immunosuppressive regimens… Expand

BACKGROUND Renal transplantation is the standard of care for patients with end-stage renal disease. Although maintenance… Expand

 

Selective inhibition of T cell costimulation using the B7-specific fusion protein CTLA4-Ig has been shown to induce long-term… Expand

The rejection of the transplanted allograft is dependent on T cell activation, which requires T cell receptor engagement by… Expand